Open access · OA
via OpenAlex
Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease
John P. Pablo, Sandra Anne Banack, Paul Alan Cox, Terence E. Johnson, Spyridon Papapetropoulos, Walter G. Bradley, A. Buck, Deborah C. Mash
Acta Neurologica Scandinavica · 2009 · ▲ 333 citations
Abstract
OBJECTIVE: The aim of this study was to screen for and quantify the neurotoxic amino acid beta-N-methylamino-L-alanine (BMAA) in a cohort of autopsy specimens taken from Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and non-neurological controls. BMAA is produced by cyanobacteria found in a variety of freshwater, marine, and terrestrial habitats. The possibility of geographically broad human exposure to BMAA had been suggested by the discovery of BMAA in brain tissues of Chamorro patients with ALS/Parkinsonism dementia complex from Guam and more recently in AD patients from North America. These observations warranted an independent study of possible BMAA exposures outside of the Guam ecosystem. METHODS: Postmortem brain specimens were taken from neuropathologically confirmed cases of 13 ALS, 12 AD, 8 HD patients, and 12 age-matched non-neurological controls. BMAA was quantified using a validated fluorescent HPLC method previously used to detect BMAA in patients from Guam. Tandem mass spectrometric (MS) analysis was carried out to confirm the identification of BMAA in neurological specimens. RESULTS: We detected and quantified BMAA in neuroproteins from postmortem brain tissue of patients from the United States who died with sporadic AD and ALS but not HD. Incidental detections observed in two out of the 24 regions were analyzed from the controls. The concentrations of BMAA were below what had been reported previously in Chamarro ALS/ Parkinsonism dementia complex patients, but demonstrated a twofold range across disease and regional brain area comparisons. The presence of BMAA in these patients was confirmed by triple quadrupole liquid chromatography/mass spectrometry/mass spectrometry. CONCLUSIONS: The occurrence of BMAA in North American ALS and AD patients suggests the possibility of a gene/environment interaction, with BMAA triggering neurodegeneration in vulnerable individuals.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/j.1600-0404.2008.01150.x
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Pablo, J.P., Banack, S.A., Cox, P.A., Johnson, T.E., Papapetropoulos, S., Bradley, W.G., Buck, A., & Mash, D.C. (2009). Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease. <em>Acta Neurologica Scandinavica</em>. https://doi.org/10.1111/j.1600-0404.2008.01150.x
Vancouver
Pablo JP, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease. Acta Neurologica Scandinavica. 2009. doi:10.1111/j.1600-0404.2008.01150.x.
BibTeX
@article{john2009Cyanob,
title = {Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease},
author = {John P. Pablo and Sandra Anne Banack and Paul Alan Cox and Terence E. Johnson and Spyridon Papapetropoulos and Walter G. Bradley and A. Buck and Deborah C. Mash},
journal = {Acta Neurologica Scandinavica},
year = {2009},
doi = {10.1111/j.1600-0404.2008.01150.x},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Neuropathology and Applied Neurobiology 2018
Citation only
Review: Somatic mutations in neurodegeneration
Kernel 2023
Open access · US-GOV
IMPACT: Investigating Mild Cognitive Impairment in Patients And Controls With TD-fNIRS
C2N Diagnostics 2023
Open access · US-GOV
Quality Improvement PrecivityAD2(TM): A Survey and Clinical Utility Study of the PrecivityAD2 Blood Test in the Evaluation of Cognitive Impairment (QUIP II)
Kessler Foundation 2023
Open access · US-GOV
Use of a Memory Technique to Improve New Learning and Memory in Individuals With Mild Cognitive Impairment
Beijing Friendship Hospital 2015
Open access · US-GOV
Monetary Cost of Alzheimer's Disease in China: Study Protocol for a Cluster Randomized Observational Study
The Journals of Gerontology Series A 2016
Preprint · OA